Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TBPH Stock Forecast 2026-2027
$16.92
Current Price
$876.93M
Market Cap
Buy 0
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to TBPH Price Targets
+12.3%
To High Target of $19.00
+0.5%
To Median Target of $17.00
+0.5%
To Low Target of $17.00
TBPH Price Momentum
-0.5%
1 Week Change
+3.7%
1 Month Change
+46.7%
1 Year Change
-9.6%
Year-to-Date Change
-19.5%
From 52W High of $21.03
+56.3%
From 52W Low of $10.82
📊 TOP ANALYST CALLS
Did TBPH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Theravance is one of their latest high-conviction picks.
Latest TBPH Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, TBPH has a neutral consensus with a median price target of $17.00 (ranging from $17.00 to $19.00). The overall analyst rating is Buy (6.0/10). Currently trading at $16.92, the median forecast implies a 0.5% upside. This outlook is supported by 0 Buy, 5 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Douglas Tsao at HC Wainwright & Co., suggesting a 0.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TBPH Analyst Ratings
0
Buy
5
Hold
0
Sell
TBPH Price Target Range
Low
$17.00
Average
$17.00
High
$19.00
Current: $16.92
Latest TBPH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TBPH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 7, 2026 | HC Wainwright & Co. | Douglas Tsao | Neutral | Downgrade | $17.00 |
| Jun 29, 2026 | Jones Trading | Hold | Downgrade | $N/A | |
| Jun 29, 2026 | BTIG | Neutral | Downgrade | $N/A | |
| Apr 7, 2026 | B. Riley Securities | Neutral | Maintains | $N/A | |
| Mar 23, 2026 | TD Cowen | Hold | Maintains | $N/A | |
| Mar 20, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Mar 5, 2026 | Oppenheimer | Perform | Downgrade | $N/A | |
| Mar 4, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 4, 2026 | B. Riley Securities | Neutral | Downgrade | $N/A | |
| Mar 3, 2026 | BTIG | Buy | Maintains | $N/A | |
| Mar 2, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 3, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Dec 3, 2025 | Oppenheimer | Outperform | Initiates | $N/A | |
| Nov 26, 2025 | BTIG | Buy | Maintains | $N/A | |
| Nov 11, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Sep 12, 2025 | B. Riley Securities | Buy | Initiates | $N/A | |
| Jun 27, 2025 | BTIG | Buy | Maintains | $N/A | |
| Jun 17, 2025 | Jones Trading | Buy | Initiates | $N/A | |
| Feb 27, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 25, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
Theravance Biopharma Inc. (TBPH) Competitors
The following stocks are similar to Theravance based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Theravance Biopharma Inc. (TBPH) Financial Data
Theravance Biopharma Inc. has a market capitalization of $876.93M with a P/E ratio of 7.6x. The company generates $109.78M in trailing twelve-month revenue with a 104.3% profit margin.
Revenue growth is +15.0% quarter-over-quarter, while maintaining an operating margin of -33.1% and return on equity of +50.2%.
Valuation Metrics
Market Cap
$876.93M
Enterprise Value
$517.08M
P/E Ratio
7.6x
PEG Ratio
-0.1x
Price/Sales
8.0x
Growth & Margins
Revenue Growth (YoY)
+15.0%
Gross Margin
N/A
Operating Margin
-33.1%
Net Margin
+104.3%
EPS Growth
+15.0%
Financial Health
Cash/Price Ratio
+45.2%
Current Ratio
13.1x
Debt/Equity
13.9x
ROE
+50.2%
ROA
+0.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Theravance Biopharma Inc. (TBPH) Business Model
About Theravance Biopharma Inc.
What They Do
Biopharmaceutical company developing respiratory and rare disease treatments.
Business Model
Theravance Biopharma generates revenue through the commercialization of its products, such as YUPELRI for COPD, and by advancing its diverse pipeline of drug candidates through strategic partnerships and collaborations. The company focuses on both internal development and external collaborations to optimize its research and development efforts.
Additional Information
The company is headquartered in South San Francisco, California, with additional offices in Dublin, Ireland. Its research facilities in the Bay Area support global clinical programs and commercialization initiatives, enhancing its ability to innovate and respond to market needs in the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
90
CEO
Mr. Rick E. Winningham M.B.A.
Country
United States
IPO Year
2014
Website
www.theravance.comTheravance Biopharma Inc. (TBPH) Latest News & Analysis
Latest News
Quick Summary
Zymeworks will acquire Theravance Biopharma for $929 million, expanding its portfolio in the biotech sector.
Why It Matters
The acquisition of Theravance by Zymeworks for $929 million signals potential growth and consolidation in the biotech sector, impacting stock valuations and investor sentiment.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
Theravance Biopharma has reached an agreement with Zymeworks for acquisition at $17 per share.
Why It Matters
Theravance Biopharma's acquisition at $17 per share indicates a premium for shareholders, affecting stock prices and investor sentiment in the biotech sector.
Source: Barrons
Market Sentiment:
Positive
Quick Summary
Theravance Biopharma will be acquired by Zymeworks for $17.00 per share in cash, totaling $929 million. Shareholders will also receive a CVR for 80% of future proceeds from ampreloxetine.
Why It Matters
Theravance Biopharma's acquisition for $17 per share offers shareholders immediate cash and potential future earnings from ampreloxetine, influencing stock valuations and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Monteverde & Associates is investigating Theravance Biopharma's sale to Zymeworks, which offers shareholders $176 per share in cash and one contingent value right.
Why It Matters
The investigation into Theravance Biopharma's sale may impact shareholder value and legal outcomes, influencing investor sentiment and stock performance for TBPH.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Ademi LLP is investigating Theravance Biopharma (NASDAQ: TBPH) for potential fiduciary duty breaches related to its transaction with Zymeworks.
Why It Matters
Concerns over potential breaches of fiduciary duty in Theravance Biopharma's transaction may impact investor confidence, stock performance, and future legal liabilities.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Halper Sadeh LLC is investigating Theravance Biopharma's sale to Zymeworks for $17.00 per share, focusing on potential violations by Theravance's board. Shareholders can seek more information.
Why It Matters
The investigation into Theravance's sale to Zymeworks may indicate potential issues with the deal or corporate governance, impacting share value and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About TBPH Stock
What is Theravance Biopharma Inc.'s (TBPH) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Theravance Biopharma Inc. (TBPH) has a median price target of $17.00. The highest price target is $19.00 and the lowest is $17.00.
Is TBPH stock a good investment in 2027?
According to current analyst ratings, TBPH has 0 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $16.92. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TBPH stock?
Wall Street analysts predict TBPH stock could reach $17.00 in the next 12 months. This represents a 0.5% increase from the current price of $16.92. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Theravance Biopharma Inc.'s business model?
Theravance Biopharma generates revenue through the commercialization of its products, such as YUPELRI for COPD, and by advancing its diverse pipeline of drug candidates through strategic partnerships and collaborations. The company focuses on both internal development and external collaborations to optimize its research and development efforts.
What is the highest forecasted price for TBPH Theravance Biopharma Inc.?
The highest price target for TBPH is $19.00 from at , which represents a 12.3% increase from the current price of $16.92.
What is the lowest forecasted price for TBPH Theravance Biopharma Inc.?
The lowest price target for TBPH is $17.00 from Douglas Tsao at HC Wainwright & Co., which represents a 0.5% increase from the current price of $16.92.
What is the overall TBPH consensus from analysts for Theravance Biopharma Inc.?
The overall analyst consensus for TBPH is neutral. Out of 2 Wall Street analysts, 0 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $17.00.
How accurate are TBPH stock price projections?
Stock price projections, including those for Theravance Biopharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 15, 2026 4:14 PM UTC